MedTrace Logo

Rate of Allergic Contact Dermatitis and Cosmetic Outcomes

NCT06957444 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 600

Last updated 2026-05-12

No results posted yet for this study

Summary

The patients from the Department of Orthopaedics Center for Joint Replacement will be asked to participate in the study. These patients will be randomized to one of three wound closure products, Sylke adhesive dressing, Exofin skin glue, or Suture Strip Plus. Participants will be asked to take a photograph of the incision 4 days after surgery to submit via MyChart for review by the WVU Department of Dermatology Team. All patients will be evaluated at their regular 2-week, 6-week, and 3-month post-operative visits where clinical photographs will be submitted for independent review by the WVU Department of Dermatology Team to assess outcomes.

Conditions

  • Allergic Contact Dermatitis
  • Osteoarthritis, Hip
  • Osteoarthritis, Knee

Interventions

PROCEDURE

Sylke Adhesive Dressing

Topical wound closure device, made from silk fibroin woven mesh coated with a pressure-sensitive acrylic adhesive.

PROCEDURE

Exofin Skin Glue

2-octil cyanoacrylate formulation, applied using a soft and flexible applicator.

PROCEDURE

Suture Strip Plus

Flexible wound closure strip designed for primary wound closure made up of macroporous non-woven polyamide with a pressure sensitive adhesive.

Sponsors & Collaborators

  • West Virginia University

    lead OTHER

Principal Investigators

  • Benjamin Frye, MD · West Virginia University Department of Orthopaedics

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-13
Primary Completion
2028-05-31
Completion
2028-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06957444 on ClinicalTrials.gov